Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OGX-427 plus Prednisone in Chemotherapy-Naive mCRPC
NCT01120470Phase 2Completed
- Sponsor
- BC Cancer
- Start
- Sep 2010
- Primary completion
- Oct 2012
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 2
01
Overview
A Phase 2 trial of apatorsen in metastatic castration-resistant prostate cancer (mCRPC), sponsored by BC Cancer. Started Sep 2010; status: completed.
02
Drugs
apatorsen
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT01120470.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01120470.